ArticleCell2018
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.
Abstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 498 papers.
0numbers the graph read from it
0cells of the map it votes in
498citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
498 citing papers in PubMed.
- Trial
- Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Trial
- Molecular underpinnings of metastatic small renal masses.JCI insight · 2026Article
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis.Nature genetics · 2026Article
- Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.Cancer discovery · 2026Article
- Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors.The journal of liquid biopsy · 2026Article
- Deep visual multi-omics profiling links morphology and molecular programs in clear cell renal cell carcinoma.EMBO molecular medicine · 2026Article
- Tumor-Induced PDPNInternational journal of molecular sciences · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Oligoprogressive renal cell carcinoma: What is the role of surgery?BJU international · 2026Review
- PBRM1-dependent PBAF targeting is required for EMT and metastasis in breast cancer.Science advances · 2026Article
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Spatial transcriptomic profiling of ovarian clear cell carcinoma reveals heterogeneity in OXPHOS and EMT gradients.Nature communications · 2026Article
- Von Hippel-Lindau disease: pathophysiological and clinical advances.Familial cancer · 2026Review
- [Molecular characteristics for poor prognosis related renal cell carcinoma with lymph metastases].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Geospatial genetic evolution and phenotypic plasticity in triple-negative breast cancer.Genome medicine · 2026Article
- Bayesian inference of tissue-migration histories in metastatic cancer from cell-lineage tracing data.Cell genomics · 2026Article
- Induced chromosomal instability in triple negative breast cancer cells promotes M2-like polarization of macrophages.Scientific reports · 2026Article
438 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
51 authors.
Samra TurajlicTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Hang XuTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Kevin LitchfieldTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Andrew RowanTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Tim ChambersTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Jose I LopezDepartment of Pathology, Cruces University Hospital, Biocruces Institute, University of the Basque Country, Barakaldo, Spain.
David NicolDepartment of Urology, the Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
Tim O'BrienUrology Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.
James LarkinRenal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Stuart HorswellDepartment of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK.
Mark StaresTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Lewis AuRenal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence London, University College London Cancer Institute, London WC1E 6DD, UK.
Ben ChallacombeUrology Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Ashish ChandraDepartment of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, London SE1 7EH, UK.
Steve HazellDepartment of Pathology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Claudia Eichler-JonssonTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Aspasia SoultatiDepartment of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Simon ChowdhuryDepartment of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Sarah RudmanDepartment of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Joanna LynchRenal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Archana FernandoUrology Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Gordon StampExperimental Histopathology Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Emma NyeExperimental Histopathology Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Faiz JabbarTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Lavinia SpainRenal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Sharanpreet LallDepartment of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Rosa GuarchDepartment of Pathology, Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
Mary FalzonDepartment of Pathology, University College London Hospitals, London WC1E 6DE, UK.
Ian ProctorDepartment of Pathology, University College London Hospitals, London WC1E 6DE, UK.
Lisa PickeringRenal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Martin GoreRenal and Skin Units, the Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK.
Thomas B K WatkinsTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK.
Sophia WardTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence London, University College London Cancer Institute, London WC1E 6DD, UK.
Aengus StewartDepartment of Pathology, Cruces University Hospital, Biocruces Institute, University of the Basque Country, Barakaldo, Spain.
Renzo DiNataleUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria F BecerraUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ed ReznikCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
James J HsiehMolecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO, USA.
Todd A RichmondRoche Sequencing Solutions, Madison, Research & Development, Madison, WI, 53719, USA.
George F MayhewRoche Sequencing Solutions, Madison, Research & Development, Madison, WI, 53719, USA.
Samantha M HillVentana Medical Systems, Tucson, AZ 85755, USA.
Catherine D McNallyVentana Medical Systems, Tucson, AZ 85755, USA.
Carol JonesVentana Medical Systems, Tucson, AZ 85755, USA.
Heidi RosenbaumRoche Sequencing Solutions, Madison, Research & Development, Madison, WI, 53719, USA.
Stacey StanislawVentana Medical Systems, Tucson, AZ 85755, USA.
Daniel L BurgessRoche Sequencing Solutions, Madison, Research & Development, Madison, WI, 53719, USA.
Nelson R AlexanderVentana Medical Systems, Tucson, AZ 85755, USA.
Charles SwantonTranslational Cancer Therapeutics Laboratory, the Francis Crick Institute, London NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence London, University College London Cancer Institute, London WC1E 6DD, UK; Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK. Electronic address: charles.swanton@crick.ac.uk.
PEACE
TRACERx Renal Consortium
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MCancer Research Institute FC001202Cancer Research UK 17786Cancer Research UK 18176Cancer Research UK 21999Cancer Research UK C50947/A18176Cancer Research UK FC001202Medical Research Council MR/L016311/1Medical Research Council MR/P014712/1NCI NIH HHS P30 CA008748Wellcome Trust FC001202
Abstract
Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with metastatic ccRCC, including two cases sampledat post-mortem. Metastatic competence was afforded by chromosome complexity, and we identify 9p loss as a highly selected event driving metastasis and ccRCC-related mortality (p = 0.0014). Distinct patterns of metastatic dissemination were observed, including rapid progression to multiple tissue sites seeded by primary tumors of monoclonal structure. By contrast, we observed attenuated progression in cases characterized by high primary tumor heterogeneity, with metastatic competence acquired gradually and initial progression to solitary metastasis. Finally, we observed early divergence of primitive ancestral clones and protracted latency of up to two decades as a feature of pancreatic metastases.
Indexed as
MutationNeoplasm MetastasisAdultAgedAged, 80 and overBiomarkersBiopsyCarcinoma, Renal CellChromosome MappingChromosomes, Human, Pair 14Chromosomes, Human, Pair 9Disease ProgressionFemaleHumansKidney NeoplasmsLongitudinal StudiesBiomarkerschromosome instabilitycytoreductive nephrectomyevolution of metastasisloss of 9pmetastasectomymetastasisoligometastasisrenal cell cancersolitary metastasis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.